

Index

- abstracts 170
- adverse drug experiences
 - (ADEs) 19, 24, 27
- adverse event reporting system
 - (AERS) 27
- advertising 5
- alpha-1 norepinephrine
 - (alpha-1) receptors 7
- Alteplase 47
- Alzheimer's disease 10, 58, 73
 - amyloid hypothesis, target identification 37
 - amyloid precursor protein (APP) 37
 - animal models 40
 - autosomal dominant forms 10
 - cholinesterase inhibitors 11, 41
 - early treatments 179
 - gold standard tool 81
 - pre-clinical development 40–1
- amines
 - biogenic amine theory, major depression 5
 - neurotransmitter systems 5
- animal models in pre-clinical development 39–41
- antibiotics 2
- antibody affinity 47
- antibody fragments 47
- antidepressants
 - evolution 4
 - history of drug development 4
 - medical writing 165
 - new 4
 - TCAs, receptor binding profiles 7–8
- antihypertensives, with ingestible wireless sensor 194
- antipsychotics
 - atypical 6, 10
 - human genome project 10
 - medical writing 163
- ATP-dependent efflux pumps 46
- authors' submission toolkit 171
- benzodiazepines 44
- Best Pharmaceuticals for Children Act (BPCA, 2002) 17
- beta-secretase *see* secretases
- biologics, pre-clinical development 46–7
- biomarker-based therapies
 - imatinib 79
 - trastuzumab 79
- biomarkers
 - algorithms 87
 - data retrospective analysis 88
 - decision tree for research program 86
 - defined 65
 - drug rescue programs 88
 - endpoints 65
 - establishing specific biomarkers 66
 - methodologies 87
 - of non-response 82
 - optimal combinations 86
 - and personalized medicine 78
 - Phase I development 66
 - Phase II development 88
 - panels 85
 - pre-clinical development 48
 - rapid identification of treatment effectiveness in major depression (BRITE-MD) 66
 - sensitivity 82
 - specificity 82
 - unbiased discovery methods 81
 - wireless health technology 196
- bipolar disorder
 - cognition defects 181
 - functional milestone rates 178
 - regulatory guidance, clinical trials management 132
- blood-brain barrier 45
- endothelial cells, astrocytic projections 45
- models 46
- tight junctions 45
- Center for Drug Evaluation and Research (CDER) 16
- centuximab 88
- chlorpromazine 3–4, 6, 33
 - binding affinity 6
 - vs. newer atypical antipsychotics 6
- cholinesterase inhibitors, Alzheimer's disease 11, 41
- Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) 169
- clinical trials information 169
 - abstracts 170
 - authors' submission toolkit 171
 - Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) 169
 - continuing medical education (CME) 172
 - effect size measures 174
 - emerging and non-English-speaking markets 175
 - journals 170
 - on-line resources, standards and guidance 173
 - presenting results 174
 - promotional programming 174
 - publication 170
 - registration of clinical trials 169
 - regulatory documents 172
 - reviews 170
 - scientific meetings 170
- clinical trials management at company level 127
- appendix 145
- case study 127
- countries accepting placebo 138

- country process for
 - regulatory and ethical submissions 137
- failure risk 127
- key considerations 130
- regulatory guidance 128
 - bipolar disorder 132
 - compliance improvement 129
 - depression 131
 - European Agency for Evaluation of Medicines (EMA) 128
 - FDA 128
 - generalized anxiety disorder 133
 - key considerations 130
 - negative symptoms 128
 - placebo use 128
 - schizophrenia 130
 - special populations 129
- study implementation 136
 - eligible patients 142, 144
 - investigators' training 140
 - managing recruitment 141
 - measuring success 143
 - monitoring quality 143
 - recruitment rates 139
 - recruitment timelines and scenario planning 138
 - site selection 139
 - start-up phase 136
 - approval requirements 136
 - countries accepting placebo 138
 - country process 137
 - time to approval 137
 - see also* Phase I trials
 - upfront planning 134
 - drug safety monitoring 135
 - feasibility study 135
 - global program 135
 - key areas 134
 - placebo arm acceptance 134
 - prevention of relapse studies 134
 - schizophrenia research activity 135
 - see also* data collection; recruitment
 - clinical trials management at site level 148
 - consent 152
 - number and selection of clinical study sites 74
 - research site 148
 - academic settings 149
 - coordinators 149
 - diverse settings 149
 - industry-funded trials 149
 - organization diagram 148
 - procedures per clinical trial 148
 - sponsor 150
 - training 150
 - see also* data collection; recruitment
 - clozapine 3
 - compliance
 - failed CNS trials, wireless health technology 196
 - innovation 198
 - regulatory guidance 129
 - continuing medical education (CME) 172
 - continuous reassessment method (CRM) 63
 - data (and data analysis) 120–1
 - longitudinal analysis 121
 - missing at random* (MAR) 121
 - missing completely at random* (MCAR) 121
 - missing not at random* (MNAR) 121
 - data collection
 - project marketing tool kit 152
 - depression
 - biogenic amine theory 5
 - major depressive disorder response rates in clinical trials 120
 - statistics issues 121
 - rapid identification of treatment
 - effectiveness in major depression (BRIDE-MD) 66
 - regulatory guidance, clinical trials management 131
 - sequenced treatment
 - alternatives to relieve depression (STAR*D) project 93
 - direct-to-patient trials 197
 - disruptive technologies driving innovation 192
 - Alzheimer's disease study 73
 - antihypertensive tablet with ingestible wireless sensor 194
 - chlorpromazine and haloperidol vs. newer atypical antipsychotics 6
 - clinical trial research activity in schizophrenia per region 135
 - comparison of receptor binding profiles of TCAs, SSRIs, and SNRIs 7
 - compliance innovation 198
 - direct-to-patient trials 197
 - drug development 192
 - drug discovery 39
 - GE V-scan device 193
 - lead generation, fragment-based approaches 43
 - new product development 197
 - patients recruited per indication per region 135
 - Phase III success rate vs. Phase II power and alpha level 117
 - REMOTE trial 197
 - wireless health technology 192–4
 - dopamine D2 receptor antagonists 33
 - dopamine neurons 36
 - dose-response, statistics issues 101
 - Drug Efficacy Study Implementation (DESI) 16
 - Drug Price Competition and Patent Term Restoration Act (1984) 16
 - Drug Safety Oversight Board (2005) 28
 - drugs
 - approval process 14, 26
 - blockbusters 1
 - classification coding 20
 - development, learn and confirm phases 57

- drugs (cont.)
 development timeline 18
 discovery 39
 disruptive technologies 192, 197
 drug-drug interaction 71
 early drugs 3, 67
 new drug application (NDA) 20, 26
 reference listed drug (RLD) 26
 rescue programs, biomarker data retrospective analysis 88
 small molecules as CNS drug candidates 45
 wireless health technology 194
- Durham-Humphrey Amendment (1951) 16
- eCTD format, regulatory issues 21
- electroencephalography (EEG) 49
- emerging and non-English-speaking markets 175
- endophenotypes 49
- ethical issues 89
 anonymity of patient 89
 data fortresses 89
 informed consent forms (ICFs) 89
- European Agency for Evaluation of Medicines (EMA), regulatory guidance 128
- event-related potentials (ERPs) 49
- extrapyramidal symptoms, medical writing 164
- fibrin 47
- Final Pediatric Rule (1998) 17
- Food and Drug Administration (FDA)
 Amendments Act (FDAAA, 2007) 17, 28
 FDA Guidances 15
 Modernization Act (FDAMA 1997) 16
 regulatory guidance 128
- Food, Drug, and Cosmetic Act (FD&C Act 1938) 15, 22
- fragment-based approaches, lead generation 43
- functional magnetic resonance imaging (fMRI) 49
- G-protein-coupled antagonists 75
- G-protein-coupled receptors 34, 42
 agonist binding 43
 venus fly trap mechanism 43
- GABA, fast inhibitory synaptic interactions 44
- GABA receptor 44
- GABA_A receptor 44
- GABA_B receptor 36
- GE V-scan device 193
- generalized anxiety disorder (GAD), regulatory guidance 133
- genomics
 Phase II development 84
- Good Laboratory Practice (GLP) regulations 18
- Guidance for Industry*, non-inferiority clinical trials 23
- haloperidol 6
 binding affinity 6
 vs. newer atypical antipsychotics 6
- Her2Neu 79
- histamine-1 (H-1) 7
- history of drug development
 advertising war 5
 Alzheimer's disease 10
 amine neurotransmitter systems 5
 antibiotic pharmacology 2
 antidepressants 4
 biogenic amine theory, major depression 5
 blockbusters 1
 early drugs 3
 human genome project 9
 receptor binding affinity 6
 receptor binding profiles 7–8
- 5-HT transporter (5-HTT) 50
- human genome project 9
 atypical antipsychotics 10
 blockbuster model 9
 cholinesterase inhibitors 10
 receptor binding profile of TCAs, SSRIs, and SNRIs 7–8
 SNRIs, SSRIs 10
- hyperprolactinemia, medical writing 164
- ICH E3 Outline for Clinical Study Reports (1996) 157
- imatinib, Phase II development 79
- industry-funded trials
see clinical trials management at site level
- informed consent forms (ICFs) 89
- innovation *see* disruptive technologies driving innovation
- interferon-beta recombinant proteins 47
- internet
 clinical trial information, standards and guidance 173
- ion channels 44
 ligand gated 44
 voltage gated 44
- journals 170
- Kefauver-Harris Amendment, regulatory issues 16
- kinases 36
- labeling 24–5
- lead compounds
 beta-secretase 42
 discovery and refinement 41
 druggability 41–2
 fragment-based approaches 43
 generation 41
 high throughput screening technologies 42
- ligand-gated ion channel family 36
- magnetic resonance imaging (MRI) 49
- magnetoencephalography (MEG) 49
- marketing, recruitment to clinical trials 150
- MATRICS consensus cognitive battery, schizophrenia 180
- MATRICS project, schizophrenia 183

- maximum tolerated single dose (MTD) 56, 60
 Phase I trials 56, 60
 medical writing 156
 antidepressants 165
 antipsychotics 163
 efficacy considerations 161
 efficacy measures 162
 examples 156
 future trends 165
 ICH E3 Outline for Clinical Study Reports (1996) 157
 measures employed in CNS studies 160
 quality of life and safety measures 163
 safety considerations 161
 melanocyte concentrating hormone
 MCH-1 antagonists 35
 MCH-1 receptor 34
 metabolic syndrome, medical writing 164
 minimum effective dose (MED) 97
 mixed-effects model for repeated measures (MMRM) 120
 monoamine reuptake inhibitors 33
 monoamine transporter gene, polymorphism 79
 monoclonal antibodies (MAbs) 46
 MRP transporters 46
 multiple ascending dose (MAD) study 55
 PK and PD multiple doses of NME 57
 multiple sclerosis 47
 muscarinic-1 acetylcholine (M-1) 7

 neuroleptic malignant syndrome, medical writing 164
 new drug application (NDA) 20, 26
 efficacy evaluation 22
 generic drug approval process 14, 26
 labeling 24–5
 safety evaluation 23
 NMDA antagonists 41

 non-English-speaking markets 175
 novel molecular entities (NMEs) 20, 55
 nuclear hormone receptors 36

 olanzepine, binding affinity 6
 omics technologies 84

 P-glycoprotein (PGP) 46
 panitumab, Phase II development 88
 Parkinson's disease 36
 gold standard tool 81
 patent term restoration 16
 Pediatric Research Equity Act (PREA, 2003) 17
 phase 47
 pharmacodynamics (PD) 56
 pharmacogenomic data submissions (2005) 29
 pharmacokinetic-pharmacodynamic (PKPD) model 71
 pharmacokinetics (PK) 56, 59
 half-life ($t_{1/2}$), dose frequency 76
 Phase I trials 55
 adaptive designs 64
 allocation rule 64
 decision rule 64
 determining optimal dose 65
 first-in-human studies 65
 response adaptive dose-ranging study designs 65
 sampling rule 64
 stopping rule 64
 Alzheimer's dementia 58
 cancer patients 60
 continuous reassessment method (CRM) 63
 dose-response curves
 shifts 61–2
 special populations 62
 drug development
 learn and confirm phases 57
 necessary conditions 61
 studies 67
 sufficient conditions 61
 escalation scheme 56
 lack of progress 58
 late Phase I vs. early Phase II studies 57

 male volunteers 60
 maximum tolerated single dose (MTD) 56, 60
 multiple ascending dose (MAD) study 55, 57
 novel molecular entities (NMEs) 55
 pharmacodynamics 56
 pharmacokinetics 56
 profile in healthy volunteers vs. participants 59
 tolerability 60
 positive and negative syndrome scale (PANSS) 59
 single ascending dose (SAD) study 55–6
 study implementation
 approval requirements 136
 countries accepting placebo 138
 country process 137
 start-up phase 136
 time to approval 137
 target modulation 63
 therapeutic index (TI) 63
 traditional approach and challenges 59
 see also biomarkers; clinical trials
 management at company level *and* clinical trials
 management at site level
 Phase II development 70
 Alzheimer's disease
 efficacy study 73
 gold standard tool 81
 biomarker data retrospective analysis 88
 centuximab 88
 drug rescue programs 88
 panitumab 88
 biomarker panels 85
 decision tree for research program 86
 optimal combinations of markers 86
 biomarkers 87
 algorithms 87
 measurement
 technologies, MRM MS 85

- Phase II development (cont.)
 of non-response 82
 and personalized medicine 78
 sensitivity 82
 specificity 82
 therapies, imatinib, trastuzumab 79
 unbiased discovery methods 81
 centuximab 88
 combining or skipping phases 78
 dose frequency 76
 pharmacokinetic half-life ($t_{1/2}$) 76
 dose selection 75
 dose-response curve 75
 drug-drug interaction 71
 efficacy measure 72
 effect size 72
 signals vs. placebo 74
 ethical issues 89
 G-protein-coupled antagonists 75
 HER2Neu 79
 in vivo receptor occupancy 75
 mechanistic hypothesis 72
 number and selection of clinical study sites 74
 omics approach
 technologies 84
 proteomic and genomic 79, 84
 single nucleotide polymorphisms (SNPs) 84
 personalized medicines and Phase II biomarkers 90
 pharmacokinetic-pharmacodynamic (PKPD) model 71
 Phase IIa and Phase II decision making 71
 Phase IIb efficacy 77
 dose-response curve characterization 78
 polymorphism of monoamine transporter gene 79
 preparation 70
 proof of concept (POC) 48, 71
 QTc prolongation 74
 quantitative measures 74
 randomization, blinding, active and placebo controls 73
 regulatory issues 88
 selection of indication 77
 single nucleotide polymorphisms (SNPs) 50, 84
 specimen collection and storage 82
 therapeutic index (TI) 72
 translatable proof of mechanism 72
 validation 89
 N-fold approach 90
see also biomarkers
 Phase III development 92
 comparators 94
 efficacy, placebo response vs. active drug 95
 placebo response 95
 dose selection 97
 minimum effective dose (MED) 97
 endpoints 96
 comparative efficacy 96
 patient-reported outcomes (PROs) 97
 initiation 92
 safety 98
 statistics issues 116
 study populations 93
 inclusion/exclusion criteria 93
 insufficient generalizability 94
 selection of patients 94
 success rate, vs. Phase II power and alpha level 117
 tolerability 98
 phenothiazines 7, 33
 Physician's Labeling Rule (PLR) 25
 placebo response
 control 119
 statistics issues 118, 120
 countries accepting placebo 138
 upfront planning, placebo arm acceptance 134
 use/regulatory guidance 128
 positive and negative syndrome scale (PANSS) 59
 positron emission tomography (PET) 49
 post-marketing commitment (PMC) 28
 post-marketing drug regulation 27
 potassium channels 36
 pre-clinical development 31
 animal models 39
 Alzheimer's disease 40–1
 behavioral effects 41
 secretase inhibitors 40
 validity 40
 beta-secretase 37
 biologics as CNS drugs 46–7
 Alteplase 47
 antibody affinity 47
 antibody fragments 47
 fibrin 47
 interferon-beta recombinant proteins 47
 monoclonal antibodies (MAbs) 46
 multiple sclerosis 47
 phage 47
 recombinant proteins 46
 recombinant tPAs 47
 ribosome display 47
 streptokinase 47
 thrombolytics, stroke treatment 47
 tissue plasminogen activator (tPA) 47
 biomarkers 48
 new developments 50
 drug discovery process 31–2
 four phases 32
 target number and diversity 32
 G-protein-coupled receptors 42
 glutamate hypothesis, schizophrenia 39
 ion channels 44
 lead compounds, discovery and refinement 41
 presenilin 37
 reverse pharmacology and multi-target agents 33–4
 schizophrenia 139
 secretases in Alzheimer's disease 37, 45
 small molecules as CNS drug candidates 45

- ATP-dependent efflux pumps 46
 blood-brain barrier 45
 blood-brain barrier models 46
 lipophilicity 46
 MRP transporters 46
 P-glycoprotein (PGP) 46
 pH trapping 46
 target class approach 34–5
 dopamine neurons 36
 drugability 42
 G-protein-coupled receptors 34
 GABA_B receptor 36
 kinases 36
 ligand-gated ion channel family 36
 MCH-1 antagonists 35
 melanocyte concentrating hormone (MCH) 34
 nuclear hormone receptors 36
 Parkinson's disease 36
 potassium channels 36
 SLC-1 in recombinant systems 35
 synaptic transmission 34
 voltage-gated ion channels 36
 target discovery 34
 target identification 37
 target validation 38, 41
 translational research, defined 48
 prepulse inhibition (PPI) 50
 Prescription Drug User Fee Act (PDUFA, 1992) 16
 presenilin 37
 promotional programming 174
 proof of concept (POC) 48, 71
 proof of mechanism (POM) 48, 72
 proof of safety (POS) 48
 proteomics 79
 Phase II development 84
 publication of trial information 170
 QTc prolongation 74
 medical writing 164
 Phase II development 74
 quality of life, and safety measures 163
 quetiapine, binding affinity 6
 receptor binding profiles, TCAs 7–8
 recombinant proteins 46
 recombinant tPAs 47
 recruitment to clinical trials 150
 access to 151
 marketing methods 150
 per indication per region 145–6
 rates 139
 timelines and scenario planning 138
 unique recruiting sites 145
 word of mouth as referral tool 151
 reference listed drug (RLD) 26
 registration of clinical trials 169
 regulatory documents 172
 regulatory guidance
 bipolar disorder 132
 clinical trials management at company level 128
 compliance improvement 129
Guidance for Industry 23
 key considerations 130
 negative symptoms 128
 placebo use 128
 schizophrenia 130
 special populations 129
 regulatory issues 14, 16
 adverse drug experiences (ADEs) 19, 24
 adverse event reporting system (AERS) 27
 Amendments Act (FDAAA, 2007) 17, 28
 approval letter 26
 Best Pharmaceuticals for Children Act (BPCA, 2002) 17
 Center for Drug Evaluation and Research (CDER) 16
 clinical drug development process 18
 contraindications 25
 drug classification coding 20
 drug development timeline 18
 Drug Efficacy Study Implementation (DESI) 16
 Drug Price Competition and Patent Term Restoration Act (1984) 16
 Drug Safety Oversight Board (2005) 28
 Durham-Humphrey Amendment (1951) 16
 eCTD format 21
 elements to assure safe use (ETASU) 24
 expanded access to treatment 20
 FD&C Act (1938) 15, 22
 FDA Guidances 15
 Final Pediatric Rule (1998) 17
 generic drug approval process 14, 26
 Good Laboratory Practice (GLP) regulations 18
 investigational new drug 17
 Kefauver-Harris Amendment 16
 labeling 24–5
 MedWatch 27–8
 new drug application (NDA) 20, 26
 new molecular entity (NME) 20
 patent term restoration 16
 Pediatric Research Equity Act (PREA, 2003) 17
 pharmacogenomic data submissions (2005) 29
 Phase I 18
 Phase II 19
 Phase III 19
 Physician's Labeling Rule (PLR) 25
 post-marketing commitment (PMC) 28
 post-marketing drug regulation 27
 post-marketing requirements (PMRs) 28
 prescribing information 25
 Prescription Drug User Fee Act (PDUFA, 1992) 16
 reference listed drug (RLD) 26
 risk evaluation and mitigation strategy (REMS) 17, 24
 Safe Use initiative 29
 safety evaluation 23
see also safety
 Sentinel System 29

- regulatory issues (cont.)
 - treatment INDs 20
 - warnings/precautions 25
- REMOTE trial, disruptive technologies 197
- research site 148
 - see also* clinical trials
 - management at site level
- reverse pharmacology 33–4
 - chlorpromazine 33
 - dopamine D2 receptor antagonists 33
 - monoamine reuptake inhibitors 33
 - and multi-target agents 33–4
 - selective inhibitors of serotonin transporters (SSRIs) 33
 - serotonin-noradrenaline reuptake inhibitors (SNRIs) 33
- reviews, clinical trial information 170
- ribosome display 47
- risk evaluation and mitigation strategy (REMS) 17, 24
- risperidone, binding affinity 6
- Safe Use initiative 29
- safety
 - drug monitoring 135
 - Drug Safety Oversight Board (2005) 28
 - elements to assure safe use (ETASU) 24
 - evaluation, regulatory issues 23
 - medical writing 161
 - MedWatch Safety Alerts 28
 - Phase III development 98
 - proof of safety (POS) 48
 - and quality of life 163
 - surveillance, wireless health technology 196
- schizophrenia
 - cognition impairments 177
 - ability score correlations 182–3
 - augmentation therapy 182
 - clinical trials management 135
 - clinical trials regulatory guidance 130, 135
 - clinical trials research activity per region 135
 - cognitive enhancement studies 185
 - compounds and mechanisms of action 185
 - drug interventions 179
 - drug interventions, results 184
 - drug pre-clinical development 139
 - drugs, enhancement research design 181
 - functional milestone rates 178
 - glutamate hypothesis 39
 - MATRICES consensus cognitive battery 180
 - MATRICES project 183
 - non-pharmacological interventions 185
 - placebo response 119
 - prediction of community activities 178
 - remediation 188
 - validation of co-primary measures 182
- dosing 186–7
 - cognitive change 187
 - concurrent treatments 187
 - functional outcomes 187
 - magnitude of effect 187
 - scheduling 186
- functional milestones 178
- pre-clinical development 139
- scientific meetings 170
- secretases
 - Alzheimer's disease 45
 - beta-secretase 45
 - gamma-secretase 37, 45
 - lead generation fragment-based approaches 43, 45
- inhibitors 40
- selective serotonin reuptake inhibitors (SSRIs) 33, 50, 79
- human genome project 10
- Phase II development 79
- receptor binding profiles 7–8
- Sentinel System 29
- serotonin-noradrenaline reuptake inhibitors (SNRIs) 33
- human genome project 10
- signal detection
 - baseline observation carried forward (BOCF) 122
 - improvement 120
 - last observation carried forward (LOCF) 120
 - mixed-effects model for repeated measures (MMRM) 120
 - wireless health technology 195
- single ascending dose (SAD) study design 55–6
- single nucleotide polymorphisms (SNPs) 50, 84
- Phase II 84
- single photon emission computerized tomography (SPECT) 49
- site *see* clinical trials management at site level
- SLC-1 in recombinant systems 35
- small molecules as CNS drug candidates 45
- specimen collection and storage
 - blood specimens 82
 - collection tube type impact 83
 - long-term storage 83
 - standard operating procedures (SOPs) 82–3
 - temperature 83
- standard operating procedures (SOPs), specimen collection 82–3
- statistics issues 100
 - adaptive designs 105
 - clinically meaningful difference (CMD) 105
 - dose-response scenarios 105
 - fixed and adaptive clinical trial simulator (FACTS) software 106
 - secondary archtypes 105
 - two-stage 107
- analytic road map 124
- axes of development 101–2
- dose-response 101
- signal detection 102

		Index	207
baseline observation carried forward (BOCF) 122	baseline severity 119	trastuzumab, Phase II development 79	
context 104	patient expectation 119	treatment INDs 20	
design archetypes 100	schizophrenia 119		
false negative results 100	and signal detection 115	validity	
false positive results 100	portfolio modeling and simulation 114	construct validity 40	
historical data 113	positive control 106	face validity 40	
last observation carried forward (LOCF) 120	outcomes 109–11	predictive validity 40	
longitudinal clinical trials 124	portfolio perspective 109, 113	voltage-gated ion channels 36	
major depressive disorder 121	quantitative evaluation 107, 112		
missing data and data analysis 120–1	primary archetypes 102	Waxman-Hatch act, regulatory issues 16	
longitudinal analysis 121	<i>fast-to-PoC</i> 102	wireless health technology 192–4	
<i>missing at random</i> (MAR) 121	<i>fast-to-registration</i> 103	biomarkers 196	
<i>missing completely at random</i> (MCAR) 121	secondary archetypes 103	clinical drug development 194	
<i>missing not at random</i> (MNAR) 121	signal detection improvement 120	efficacy measures in trials 196	
observational and causal components 117–18	mixed-effects model for repeated measures (MMRM) 120	safety surveillance, post approval 196	
optimum for portfolio 104	standard of care comparisons 111	signal detection 195	
outcomes	streptokinase 47	subject compliance and failed CNS trials 196	
causal pathways 118	stroke, thrombolytics 47	wireless technology for remote care and monitoring 193	
positive controls 111	synaptic transmission 34		
probabilities 108, 110		world countries	
Phase III	therapeutic index (TI)	accepting placebo 138	
portfolio attributes 116	Phase I trials 63	process for regulatory and ethical submissions 137	
success rate vs. Phase II power and alpha level 117	Phase II development 72	start-up phase, clinical trials management at company level 137	
placebo response control 118, 120	thioridazine 3		
	thrombolytics 47		
	tissue plasminogen activator (tPA) 47		
	translational research 48, 72 defined 48		
		ziprasidone, binding affinity 6	